Wednesday, June 28
(13:15 – 14:15 CEST)
| 13:15-13:20 | Welcome and introduction | Prof. Norbert Pfeiffer (Germany) |
| 13:20-13:35 | Exploring a new path taken: The latest evidence on a novel therapeutic strategy in Europe | Prof. Francesco Oddone (Italy) |
| 13:35-13:45 | Insights into the road less travelled: Real-life experience on the use of netarsudil/latanoprost fixed-dose combination | Prof. Verena Prokosch (Germany) |
| 13:45-13:55 | At the intersection of positive patient outcomes: Can we provide consistent IOP control without compromising patients’ quality of life? | Prof. Gábor Holló (Hungary) |
| 13:55-14:10 | Looking at the journey ahead: A long-term outlook on the effectiveness and safety of ab externo LIGS | Prof. Julián García Feijóo (Spain) |
| 14:10-14:15 | Summary and closing remarks | Prof. Norbert Pfeiffer (Germany) |
Thursday, June 29
(7:30 – 8:30 CEST)
Thursday, June 29
(7:30 – 8:30 CEST)
| 07:30-07:35 | Welcome and introduction | Prof. Stefano Gandolfi (Italy) |
| 07:35-07:55 | A Lasting Legacy: Ensuring The Future Of Glaucoma Management | Prof. Catherine Birt (United Kingdom) |
| 07:55-08:15 | Optimizing Glaucoma Management: From Research to Clinical Practice | Prof. Francesca Cordeiro (United Kingdom) |
| 08:15-08:25 | Q&A and panel discussion | All |
| 08:25-08:30 | Closing remarks | Prof. Stefano Gandolfi (Italy) |
Thursday, June 29
(12:15 – 13:15 CEST)
Thursday, June 29
(18:00 – 19:00 CEST)
Speaker 1: Prof. Christopher Kai-shun Leung, MD
“360 degree evaluation of iris trabecular contact with anterior segment optical coherence tomography for detection of primary angle closure disease”
Speaker 2: Felix Gonzalez-Lopez, MD, PhD
” Glaucoma and ICL Significance of the trabecular angle in posterior chamber phakic intraocular lens surgery”
Thursday, June 29
(18:00 – 19:00 CEST)
Moderators: Ike Ahmed & Keith Barton
| 18:03-18:07 | Welcome | Keith Barton (United Kingdom) |
| 18:07-18:15 | Unmet needs in glaucoma treatment | Ike Ahmed (Canada) |
| 18:15-18:20 | Today and tomorrows surgical paradigm | Keith Barton (United Kingdom) |
| 18:20-18:27 | Adopting ELIOS: Technique & Learning curve | Alice Grise-Dulac (France) |
| 18:27-18:34 | Long-term experience with ELIOS | Anselm Juenemann (Germany) |
| 18:34-18:41 | The impact of ELIOS on disease progression | Antonio Moreno-Valladares (Spain) |
| 18:41-18:56 | Q&A and discussion | All |
| 18:56-19:00 | Final remarks | Ike Ahmed & Keith Barton |
Thursday, June 29
(18:00 – 19:00 CEST)
| 18:00-18:05 | Laying the foundations: Welcome and introduction | Prof. Ingeborg Stalmans (Belgium) |
| 18:05-18:20 | Hiding in plain sight: PAPS and the clinical experience with omidenepag isopropyl | Prof. Masaki Tanito (Japan) |
| 18:20-18:35 | A tale of two pathways: Clinical and real-world insights on the use of netarsudil as monotherapy and in fixed-dose combination with latanoprost | Prof. Jella An (United States) |
| 18:35-18:45 | The evolving surgical landscape: Contemporary approaches and practical insights into the role of ab externo LIGS | Prof. Ingeborg Stalmans (Belgium) |
| 18:45-18:55 | Panel discussion and debate | All; chaired by Prof. Ingeborg Stalmans (Belgium) |
| 18:55-19:00 | Summary and close | Prof. Ingeborg Stalmans (Belgium) |
Thursday, June 29
(18:00 – 19:00 CEST)
| Official opening Welcome / General session | Dr. Alessio Martucci, MD, PhD (Italy) |
| Glaucoma treatment options: when laser treatment is not enough | Professor Gus Gazzard (United Kingdom) |
| Optimising glaucoma diagnosis | Mr. Andrew Tatham (United Kingdom) |
| Why is Neuroprotection a step not to miss? | Professor Piero Barbanti (Italy) |
| IOP independent therapies for glaucomatous neurodegeneration | Professor Colin E. Willoughby (Ireland) |
Thursday, June 29
(18:00 – 19:00 CEST)
| 18:00 | Advantages and opportunities of the supraciliary space | Steve Sarkisian (Chair) |
| 18:15 | Who can benefit from supraciliary MIGS? Patient selection with MINIject | Karsten Klabe |
| 18:30 | Intraoperative and postoperative safety of supraciliary MIGS: Experience report after one year of MINIject implantations | Faisal Ahmed |
| 18:45 | Sustainable effectiveness of MINIject: 3 year pooled data for the STAR-GLOBAL – study | Inder Paul Singh |
Friday, June 30
(7:30 – 8:30 CEST)
Moderator: Dr. Paul Singh
Friday, June 30
(7:30 – 8:30 CEST)
Speakers: Chelvin Sng, Karsten Klabe, Leon Au
Topic:
Friday, June 30
(7:30 – 8:30 CEST)
| Welcome by the program | Chair – Robert Weinreb, MD |
| Use of a large, real-world population database to develop AI tools for glaucoma | Miriam Kolko, MD, PhD |
| Structure-function and repeatability agreement between a new, bi-field VF technology and HFA | Takashi Nishida, MD, PhD |
| Optimization and utilization of glaucoma clinical decision support systems | Jithin Yohannan, MD, MPH |
| Diagnostic efficacy of retinal nerve fiber layer optical texture analysis (ROTA) of Maestro2 and Triton wide-field scans | Chris Leung, MD |
| Audience Q&A | Program Chair |
| Concluding remarks | Program Chair |
Friday, June 30
(7:30 – 8:30 CEST)
Friday, June 30
(12:15 – 13:15 CEST)
Friday, June 30
(18:00 – 19-00 CEST)
Topics:
Application of the Zeiss Glaucoma workflow.
This will include discussion of OCT analysis, Visual Field indices, detecting progression using FORUM, and incorporating SLT into clinical practice.
Panel:
Moderator – Gus Guzzard, Speakers – Ryo Asaoka, Matteo Sacchi, Paul Singh
Friday, June 30
(18:00 – 19-00 CEST)
Professor K. Sheng Lim, St Thomas’ Hospital & King’s College London
Mr. Gokulan Ratnarajan, Queen Victoria NHS Trust, East Grinstead, UK
Robert J. Noecker, M.D., Ophthalmic consultants of Connecticut, Fairfield, CT. Yale University school of medicine, New Haven, CT, USA.
Juan Carlos Izquierdo, M.D., Clinica de Ojos OftalmoSalud, Lima, Peru
Topics Discussed:
Please contact our Professional Congress Organizer MCI for all your WGC-2023 questions wgc@mci-group.com
MCI The Netherlands
Schipluidenlaan 4
1062 HE Amsterdam
The Netherlands
Thursday, June 29
(7:30 – 8:30 CEST)
| 7.30-7.35 | Welcome and Introductions | Chair: Ike Ahmed (Canada) |
| 7.35-7.50 | Clinically meaningful VF progression and determine Target IOP | Dan Lindfield (United Kingdom) |
| 7.50-8.05 | Will artificial intelligence transform Glaucoma care in future? | Ingeborg Stalmans (Belgium) |
| 8.05-8.20 | Changing dimensions in surgical options: Blebless MIGS vs MIBS | Ike Ahmed (Canada) |
Thursday, June 29
(12:15 – 13:15 CEST)
| 12:15-12:20 | Welcome | Stefano Gandolfi (Italy) |
| 12:20-12:35 | Limitations of drop therapy | Francesco Oddone (Italy) |
| 12:35-12:50 | SLT in RCTs vs. RWE | Anthony Khawaja (United Kingdom) |
| 12:50-13:05 | Targeted Delivery: Role of MMPs in the outflow pathways | Ike Ahmed (Canada) |
| 13:05-13:15 | Q&A and discussion | Stefano Gandolfi (Italy) |
Friday, June 30
(12:15 – 13:15 CEST)
Chairs:
Speakers:
| Time | Title | Presenter |
| 12:15–12:20 | Symposium agenda and objectives | Carlo Traverso (Italy) |
| 12:20–12:33 | Are we ready to change our approach to glaucoma management? | Roberto Carassa (Italy) |
| 12:33–12:46 | A step forward in the interventional glaucoma approach with XEN®63 in patients with primary open-angle-glaucoma | Antonio Fea (Italy) |
| 12:46–12:59 | Maximize the micro-incisional XEN®63 surgery option at the right time: pre-operative preparation, surgery technique and post-operative care | Michele Figus (Italy) |
| 12:59–13:15 | Faculty discussion | Stefano Gandolfi (Italy) Jose M. Martinez de la Casa (Spain) Carlo Traverso (Italy) |
XEN® Gel Implant is a CE Marked class III Medical Device. CE2797
XEN® Gel Implant is intended to reduce intraocular pressure in patients with primary open angle glaucoma where previous medical treatments have failed.
Materials developed in accordance with CE mark.
Registration conditions and licenses differ internationally, please refer to your local Directions for Use. A list of countries with this product/ indication is available from ukmedinfo@abbvie.com For further information please consult your country Directions For Use.
Adverse events should be reported to your Ministry of Health and local AbbVie office.
Medical devices have associated risks, please refer to the contraindications, warnings and precautions sections in the Directions For Use.
Promotional symposium organised and funded by Abbvie.
ALL-XEN-230005 – April 2023